For too long, people living with rare diseases have faced uncertainty, delays, and unacceptable variation in the care they receive. The launch of this quality standard is a watershed moment. For the ...

Looking ahead, the biosimilar taskforce will become a strategic cornerstone of the NICE Whole Lifecycle Approach programme, the 10-Year Health Plan and the drive for rapid uptake of biosimilars. This ...

NICE recommended rimegepant in 2023 for treating migraine and preventing episodic attacks (between 4 and 14 migraines per month), and atogepant in 2024 for preventing both episodic and chronic ...

NICE is unable to make a recommendation on canagliflozin (Invokana) for treating type 2 diabetes in children and young people 10 to 17 years. This is because the company did not provide an evidence ...

More than 80,000 adults and teenagers across England suffering with a chronic skin condition could have their lives transformed after NICE today (Tuesday, 24 February) recommended the first licensed ...

People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...

Nice has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and progressive metabolic disorder, for routine use in the NHS in England.

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. This ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not ...

This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE ...